Calcium channel blockers are indicated to treat which dysrhythmia
|
[24732]Grossman E, Messerli FH, Grodzicki T, et al. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies? JAMA 1996;276:1328-31. Show [25454]Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998;64:177-82. [27736]Beylot C, Doutre M, Beylot-Barry M. Acute generalized exanthematous pustulosis. Semin Cutan Med Surg 1996;15(4):244-249. [28277]Cardizem CD (diltiazem) package insert. Bridgewater, NJ: Bausch Health US, LLC.; 2020 Mar. [29198]Sandimmune (cyclosporine) package insert. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2015 Mar. [31978]Jerling M, Huan B, Leung K, et al. Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol 2005;45:422-33. [45649]Neumar RW, Otto CW, Link MS, et al. Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010;122:S729-S767. [50075]McDonagh MS, Eden KB, Peterson K. Drug Class Review on Calcium Channel Blockers. Portland, Oregon: OHSU; March, 2005. Oregon Health & Science University. [50076]Elliott WJ, Ram CV. Calcium channel blockers. J Clin Hypertens (Greenwich ). 2011;13(9):687-689 [50078]Jones DW, Hall JE. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and evidence from new hypertension trials. Hypertension. 2004;43(1):1-3. [50079]Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Blood Press. 2009;18(6):308-347. [50080]Tomassoni D, Lanari A, Silvestrelli G, Traini E, Amenta F. Nimodipine and its use in cerebrovascular disease: evidence from recent preclinical and controlled clinical studies. Clin Exp Hypertens. 2008;30(8):744-766. [50081]Costanzo P, Perrone-Filardi P, Petretta M, et al. Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients. J Hypertens. 2009;27(6):1136-1151. [50083]The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-2997. [50085]Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010;375(9718):906-915. [50086]Chen N, Zhou M, Yang M, et al. Calcium channel blockers versus other classes of drugs for hypertension. Cochrane Database Syst Rev. 2010(8):CD003654. [50087]Sciarretta S, Palano F, Tocci G, Baldini R, Volpe M. Antihypertensive treatment and development of heart failure in hypertension: a Bayesian network meta-analysis of studies in patients with hypertension and high cardiovascular risk. Arch Intern Med. 2011;171(5):384-394. [50088]Makani H, Bangalore S, Romero J, et al. Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate--a meta-analysis of randomized trials. J Hypertens. 2011;29(7):1270-1280. [50090]Lenert LA, Linde-Zwirble W, Newbold R, III, Korenblat BM, Doherty J, Smith ME. Using administrative data to compare the relative effectiveness of amlodipine vs nifedipine CC. Am J Manag Care. 1999;5(12):1535-1540 [50091]White WB, Saunders E, Noveck RJ, Ferdinand K. Comparative efficacy and safety of nisoldipine extended-release (ER) and amlodipine (CESNA-III study) in African American patients with hypertension. Am J Hypertens. 2003;16(9 Pt 1):739-745. [50092]Manzo BA, Matalka MS, Ravnan SL. Evaluation of a therapeutic conversion from amlodipine to felodipine. Pharmacotherapy. 2003;23(11):1508-1512. [50094]Menzin J, Lang K, Elliott WJ, et al. Adherence to calcium channel blocker therapy in older adults: a comparison of amlodipine and felodipine. J Int Med Res. 2004;32(3):233-239. [50095]Hamada A, Ishii J, Doi K, et al. Increased risk of exacerbating gastrointestinal disease among elderly patients following treatment with calcium channel blockers. J Clin Pharm Ther. 2008;33(6):619-624. [50096]Mahgoub AA, El-Medany AH, Abdulatif AS. A comparison between the effects of diltiazem and isosorbide dinitrate on digoxin pharmacodynamics and kinetics in the treatment of patients with chronic ischemic heart failure. Saudi Med J. 2002;23(6):725-731 [50097]Rodin SM, Johnson BF, Wilson J, Ritchie P, Johnson J. Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. Clin Pharmacol Ther. 1988;43(6):668-672. [50865]Aronow WS, Fleg JL, Pepine CJ, et al. ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Soc Hypertens. 2011;5:259-352. [60469]DeSchryver N, Wittebole X, VandenBergh P, et al. Severe rhabdomyolysis associated with simvastatin and role of ciprofloxacin and amlodipine coadministration. Case Rep Nephrol 2015. Epub ahead of print, doi: 10.1155/2015/761393. [60742]Health Care Financing Administration. Interpretive Guidelines for Long-term Care Facilities. Title 42 CFR 483.25(l) F329: Unnecessary Drugs. Revised 2015. [62854]Whelton PK, Carey RM, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017;S0735-1097:41519-1. Which calcium channel blockers are indicated for cardiac dysrhythmias?Verapamil is the prototype calcium antagonist and has the most clearly defined antiarrhythmic properties. Other agents in the class include D-600 (gallopamil), tiapamil, nifedipine, and diltiazem.
What conditions are calcium channel blocker medications indicated?Cardiovascular indications include hypertension, coronary spasm, angina pectoris, supraventricular dysrhythmias, hypertrophic cardiomyopathy, and pulmonary hypertension. In addition to these, they are also prescribed for Raynaud phenomenon, subarachnoid hemorrhage, and migraine headaches.
Are calcium channel blockers used for atrial fibrillation?The calcium channel blockers diltiazem (Cardizem) and verapamil (Calan, Isoptin) are effective for initial ventricular rate control in patients with atrial fibrillation. These agents are given intravenously in bolus doses until the ventricular rate becomes slower.
How does blocking calcium channels help resolve arrhythmias?L-type calcium-channel blockers decrease conduction velocity and prolong the antegrade AV node–refractory periods, helping terminate an AV node–dependent SVT. These drugs can also terminate atrial tachycardia, which is caused by triggered activity.
|
